Free Trial

Karyopharm Therapeutics (KPTI) Competitors

Karyopharm Therapeutics logo
$5.93 -0.10 (-1.66%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$5.98 +0.04 (+0.76%)
As of 10/17/2025 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KPTI vs. CRBP, FBRX, DERM, FATE, PLX, IPHA, TNXP, FTLF, AVTX, and BHST

Should you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Corbus Pharmaceuticals (CRBP), Forte Biosciences (FBRX), Journey Medical (DERM), Fate Therapeutics (FATE), Protalix BioTherapeutics (PLX), Innate Pharma (IPHA), Tonix Pharmaceuticals (TNXP), FitLife Brands (FTLF), Avalo Therapeutics (AVTX), and BioHarvest Sciences (BHST). These companies are all part of the "pharmaceutical products" industry.

Karyopharm Therapeutics vs. Its Competitors

Karyopharm Therapeutics (NASDAQ:KPTI) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Karyopharm Therapeutics has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.84, suggesting that its stock price is 184% more volatile than the S&P 500.

Karyopharm Therapeutics currently has a consensus target price of $18.20, indicating a potential upside of 206.91%. Corbus Pharmaceuticals has a consensus target price of $45.43, indicating a potential upside of 135.14%. Given Karyopharm Therapeutics' higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Corbus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Karyopharm Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Corbus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90

Corbus Pharmaceuticals has lower revenue, but higher earnings than Karyopharm Therapeutics. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karyopharm Therapeutics$145.24M0.35-$76.42M-$14.59-0.41
Corbus PharmaceuticalsN/AN/A-$40.21M-$4.76-4.06

In the previous week, Karyopharm Therapeutics had 9 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 14 mentions for Karyopharm Therapeutics and 5 mentions for Corbus Pharmaceuticals. Karyopharm Therapeutics' average media sentiment score of 0.73 beat Corbus Pharmaceuticals' score of 0.72 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Karyopharm Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corbus Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Corbus Pharmaceuticals has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -90.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Karyopharm Therapeutics-90.02% N/A -84.28%
Corbus Pharmaceuticals N/A -43.65%-39.62%

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 2.8% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 4.0% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Corbus Pharmaceuticals beats Karyopharm Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Karyopharm Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KPTI vs. The Competition

MetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$51.41M$2.62B$6.13B$10.55B
Dividend YieldN/A57.79%5.72%4.83%
P/E Ratio-0.4123.3185.7827.06
Price / Sales0.35778.09612.92132.30
Price / CashN/A27.2425.8230.35
Price / Book-0.275.3212.226.58
Net Income-$76.42M$33.06M$3.33B$276.84M
7 Day Performance5.52%-0.91%0.67%-0.72%
1 Month Performance9.61%7.35%6.88%2.16%
1 Year Performance-54.56%-5.13%58.88%34.63%

Karyopharm Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KPTI
Karyopharm Therapeutics
4.2959 of 5 stars
$5.93
-1.7%
$18.20
+206.9%
-54.6%$51.41M$145.24M-0.41380
CRBP
Corbus Pharmaceuticals
4.1299 of 5 stars
$16.32
+5.0%
$45.43
+178.4%
+4.9%$190.45MN/A-3.4340News Coverage
FBRX
Forte Biosciences
2.7832 of 5 stars
$14.75
-3.4%
$68.00
+361.0%
+155.4%$189.85MN/A-0.915News Coverage
Analyst Downgrade
Options Volume
DERM
Journey Medical
2.0001 of 5 stars
$7.00
-2.9%
$12.17
+73.8%
+17.6%$189.69M$56.13M-18.4290
FATE
Fate Therapeutics
4.1576 of 5 stars
$1.39
-15.0%
$3.30
+137.4%
-54.5%$188.56M$13.63M-0.96550
PLX
Protalix BioTherapeutics
2.1087 of 5 stars
$2.45
+3.8%
$15.00
+512.2%
+70.6%$188.17M$61.95M-18.85200Gap Down
IPHA
Innate Pharma
2.0843 of 5 stars
$1.93
-4.9%
$6.50
+236.8%
+6.4%$187.13M$21.77M0.00220Gap Up
TNXP
Tonix Pharmaceuticals
2.7851 of 5 stars
$20.06
-5.3%
$70.00
+249.0%
+3.4%$185.75M$10.09M-0.5150Short Interest ↑
FTLF
FitLife Brands
3.5511 of 5 stars
$20.15
+2.3%
$23.00
+14.1%
+13.2%$185M$64.47M23.9920
AVTX
Avalo Therapeutics
2.9471 of 5 stars
$13.67
-2.0%
$31.67
+131.7%
+37.3%$183.48M$440K0.0040News Coverage
Positive News
Analyst Forecast
Short Interest ↑
BHST
BioHarvest Sciences
2.124 of 5 stars
$12.50
+13.2%
$13.67
+9.3%
N/A$181.33M$25.19M-17.86N/AAnalyst Upgrade
Short Interest ↑

Related Companies and Tools


This page (NASDAQ:KPTI) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners